Company: IOBT
Filing Date: 2025-07-24
Form Type: S-3
Source: 0001193125-25-164495
Chunk: 17

Company: IO Biotech, Inc.
Filing Date: 2025-07-24
Form: S-3
Chunk 17
---
 |     | Percentage of 
 common stock  
 beneficially  
 owned         |     |   |
| European Investment Bank |     |                           | 9,845,531 | -1 |     |               | 13.0 | % |     |              | 4,221,867 |     |                          | 5,623,664 |     |               | 7.4 | % |

| (1) | Consists of (i) 4,221,867 shares of our common stock issuable upon the exercise of the Tranche B Warrants                                                                                                         
 issued under the Warrant Issuance Agreement and (ii) 5,623,664 shares of our common stock issuable upon the exercise of the Tranche A Warrants. The principal business address of the European Investment Bank is 
 98-100 boulevard Konrad Adenauer, L-2950 Luxembourg.                                                                                                                                                              |

12

PLAN OF DISTRIBUTION The selling stockholders, including their pledgees, donees, transferees, distributees, beneficiaries or other successors in interest, may from time to time offer some or all of the shares of our common stock offered under this prospectus. We will not receive any of the proceeds from the sale of the shares of our common stock offered under this prospectus by the selling stockholders. We will bear all fees and expenses incident to our obligation to register the shares of our common stock offered under this prospectus. The selling stockholders may sell all or a portion of the shares of our common stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of our common stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of our common stock may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-countermarket or in transactions otherwise than on these exchanges or systems or in the over-the-countermarket and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at privately negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The selling stockholders may use any one or more of the following methods when disposing of shares of our common stock or interests therein:

| •